中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
The Chinese Journal of Clinical Pharmacology
2015年
19期
1910-1912
,共3页
2型糖尿病%二甲双胍%沙格列汀%空腹血糖%糖化血红蛋白
2型糖尿病%二甲雙胍%沙格列汀%空腹血糖%糖化血紅蛋白
2형당뇨병%이갑쌍고%사격렬정%공복혈당%당화혈홍단백
type 2 diabetes mellitus%metformin%saxagliptin%fasting plasma glucose%hemoglobin A1c
目的 观察单用二甲双胍血糖控制不佳的2型糖尿病患者分别联用沙格列汀与格列美脲的临床疗效和安全性.方法 60例单用二甲双胍血糖控制仍不达标的2型糖尿病患者,随机分为试验组和对照组各30例. 2组均保持原来二甲双胍剂量和用法不变,试验组口服沙格列汀5 mg,每天1次;对照组早餐前口服格列美脲1~4 mg,每天1次,2组均治疗12周. 观察治疗前后患者空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、血脂和空腹胰岛素( FINS)、胰岛β细胞功能指数( HOMA-β)等指标变化情况. 结果 治疗后,2组患者FPG、2 h PG及HbA1c显著低于治疗前(P<0.05),但组间差异无统计学意义. 治疗后,试验组与对照组相比,FINS、HOMA-β明显改善( P<0.05 ). 2组均无严重不良反应,试验组轻度低血糖发生率较对照组低( P <0.05 ).结论 沙格列汀在单用二甲双胍血糖控制不佳的2型糖尿病患者中与格列美脲的降糖疗效相当,但沙格列汀可更显著改善胰岛β细胞功能,且低血糖发生率更低.
目的 觀察單用二甲雙胍血糖控製不佳的2型糖尿病患者分彆聯用沙格列汀與格列美脲的臨床療效和安全性.方法 60例單用二甲雙胍血糖控製仍不達標的2型糖尿病患者,隨機分為試驗組和對照組各30例. 2組均保持原來二甲雙胍劑量和用法不變,試驗組口服沙格列汀5 mg,每天1次;對照組早餐前口服格列美脲1~4 mg,每天1次,2組均治療12週. 觀察治療前後患者空腹血糖(FPG)、餐後2 h血糖(2 h PG)、糖化血紅蛋白(HbA1c)、血脂和空腹胰島素( FINS)、胰島β細胞功能指數( HOMA-β)等指標變化情況. 結果 治療後,2組患者FPG、2 h PG及HbA1c顯著低于治療前(P<0.05),但組間差異無統計學意義. 治療後,試驗組與對照組相比,FINS、HOMA-β明顯改善( P<0.05 ). 2組均無嚴重不良反應,試驗組輕度低血糖髮生率較對照組低( P <0.05 ).結論 沙格列汀在單用二甲雙胍血糖控製不佳的2型糖尿病患者中與格列美脲的降糖療效相噹,但沙格列汀可更顯著改善胰島β細胞功能,且低血糖髮生率更低.
목적 관찰단용이갑쌍고혈당공제불가적2형당뇨병환자분별련용사격렬정여격렬미뇨적림상료효화안전성.방법 60례단용이갑쌍고혈당공제잉불체표적2형당뇨병환자,수궤분위시험조화대조조각30례. 2조균보지원래이갑쌍고제량화용법불변,시험조구복사격렬정5 mg,매천1차;대조조조찬전구복격렬미뇨1~4 mg,매천1차,2조균치료12주. 관찰치료전후환자공복혈당(FPG)、찬후2 h혈당(2 h PG)、당화혈홍단백(HbA1c)、혈지화공복이도소( FINS)、이도β세포공능지수( HOMA-β)등지표변화정황. 결과 치료후,2조환자FPG、2 h PG급HbA1c현저저우치료전(P<0.05),단조간차이무통계학의의. 치료후,시험조여대조조상비,FINS、HOMA-β명현개선( P<0.05 ). 2조균무엄중불량반응,시험조경도저혈당발생솔교대조조저( P <0.05 ).결론 사격렬정재단용이갑쌍고혈당공제불가적2형당뇨병환자중여격렬미뇨적강당료효상당,단사격렬정가경현저개선이도β세포공능,차저혈당발생솔경저.
Objective To observe the effect and safety of metformin com-bined with saxagliptin or glimepiride in patients with type 2 diabetes me-llitus inadequately controlled with metformin alone .Methods Sixty pa-tients with type 2 diabetes mellitus inadequately controled by metformin alone were randomly divided into trial group and control group , 30 pa-tients in each group .The two groups maintain the original dose of met-formin and usage unchanged , patients in trial group were given oral saxa-gliptin 5 mg, once a day , and the patients in control group were treated with glimepiride 1-4 mg once daily before breakfast .The treatment las-ted 12 weeks.The data of fasting plasma glucose ( FPG) , 2 h postpran-dial plasma glucose(2 h PG), hemoglobin A1c(HbA1c), lipids weight, fasting insulin ( FINS) , homeostasis model assessment of β-cell function ( HOMA -β) were recorded and compared between the two groups . Results The serum levels of FPG , 2 h PG and HbA1 c were significantly decreased in two groups after treatment ( P<0.05 ) , but had no signifi-cant differences between the two groups .Compared with control group , the levels of FINS and HOMA-βstatistically increased after treatment in the trial group ( P <0.05 ) .There was no serious adverse reaction in both groups during the treatment , the incidence of mild hypoglycemia was significantly less in trial group ( P<0.05 ) . Conclusion The blood glucose control of saxagliptin is comparable to glimepiride , but saxagliptin showed a better effect on the improvement of β-cell function and decrease of the risk of hypoglycaemia .
